XpresCheck® Opens COVID-19 Testing Facility at Orlando International Airport
XpresSpa Group, Inc. (Nasdaq: XSPA) has opened a new XpresCheck® COVID-19 testing facility at Orlando International Airport. Located pre-security in the South Walk area of the Main Terminal, the facility offers Rapid RT-PCR and standard PCR testing options to meet the strong demand for reliable COVID-19 testing among travelers. The company aims to enhance public health surveillance and support biosecurity efforts amid ongoing concerns regarding COVID-19 variants. With 16 locations in 13 domestic airports, XpresCheck continues to expand its footprint in the health and wellness sector.
- Opening of a new COVID-19 testing facility at Orlando International Airport enhances service offerings.
- Strong demand for COVID-19 testing supports potential revenue from travelers, especially for international trips.
- Strategic expansion with 16 locations in 13 airports strengthens market position.
- None.
Located pre-security in the South Walk area of the Main Terminal
ORLANDO, Fla., March 30, 2022 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, today announced that it has opened a new XpresCheck® COVID-19 testing facility at Orlando International Airport (MCO).
XpresCheck is located pre-security, in the South Walk area in the Main Terminal. COVID-19 testing options include a Rapid RT-PCR test and the standard Polymerase Chain Reaction (PCR) Test.
Scott Milford, XpresSpa CEO, said, "We are pleased to be opening a convenient XpresCheck testing facility at Orlando International Airport. Demand for reliable COVID-19 testing remains strong as passengers seek to travel, especially to international destinations. Orlando has been a great market for our XpresSpa wellness locations and we are pleased to be able to complement that offering with health services through XpresCheck.”
“The continuation of airport programs like this one helps us to further enhance our public health surveillance of emerging infectious diseases that have traditionally focused on health clinics after the onset of symptoms, but with the new variant Omicron sub-lineage BA.2 and BA.3 continuing to circulate globally, new openings at locations such as Orlando International Airport help support our continued biosecurity efforts and underscore the importance of continued public-private partnerships,” said Ezra Ernst, CEO, XpresCheck.
About XpresSpa Group, Inc.
XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading global health and wellness holding company operating three distinct brands: XpresCheck®, XpresSpa®, Treat™. XpresCheck is a leading on-site airport provider of COVID-19 screening and testing with 16 locations in 13 domestic airports. XpresSpa is a leading airport retailer of spa services and related health and wellness products, with 45 locations in 21 airports globally. Treat is a travel health and wellness brand that is providing on-demand access to healthcare through technology and personalized services. The Company also recently acquired HyperPointe™, a leading digital healthcare and data analytics relationship marketing agency servicing the global healthcare and pharmaceutical industry.
To learn more about XpresSpa Group, visit: www.XpresSpaGroup.com
To learn more about XpresCheck, visit: www.XpresCheck.com
To learn more about XpresSpa, visit: www.XpresSpa.com
To learn more about Treat, visit: www.Treat.com
To learn more about HyperPointe, visit: www.Hyperpointe.com
Twitter: @xprescheck and Instagram: @realxprescheck
Twitter: @XpresSpa and Instagram: @XpresSpa
Twitter: @Treat_Care and Instagram: @treat_care
Forward-Looking Statements
This press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. Forward-looking statements relating to expectations about future results or events are based upon information available to XpresSpa Group as of today's date and are not guarantees of the future performance of the Company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in XpresSpa Group’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XpresSpa Group, or other matters and attributable to XpresSpa Group or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XpresSpa Group does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.
Investor Relations:
ICR
Raphael Gross
ir@xpresspagroup.com
(203) 682-8253
Media:
Julie Ferguson
Julie@jfprmedia.com
(312) 385-0098
FAQ
What is the latest announcement from XpresSpa Group regarding COVID-19 testing?
Where is the new XpresCheck testing facility located?
What COVID-19 testing options are available at the new facility?
How many locations does XpresCheck have in airports?
Who commented on the opening of the new XpresCheck facility?
